Series (Part Three): Living with GORD

Written by: Dr Andrew Thillainayagam
Published:
Edited by: Karolyn Judge

Consultant physician and gastroenterology specialist, Dr Andrew Thillainayagam and Dr Neil Galletly, clinical research fellow, consider the impact of gastro-oesophageal reflux disease (GORD) diagnosis and how it can be managed.

Day-to-day life, surgical options and complications of GORD are explained in part three of this series of articles.

 

Red and green chillies

 

How can GORD be managed?

It’s important to remember that, while GORD is a recurring condition that once starts doesn’t end, symptoms can be relieved. Oesophagitis can also be healed.

PPIs are the most effective way to assist in this but lifestyle modification, antacids and H2-receptor antagonists (H2RAs) can play a small part in management of mild GORD. Antacids are useful for infrequent GORD episodes or heartburn after meals and can be used alongside H2RAs. However, antacids should not be used for frequent heartburn.  

Modifications to lifestyle can all help but medical assistance should always be sought if symptoms continue.

  • Stopping smoking
  • Losing weight
  • Avoidance of food and drinks like spicy foods, coffee and alcohol  

It should be noted that food avoidance doesn’t affect symptoms at night time.

 

 

Are PPIs a treatment that patients can use every day?

Infrequent mild symptoms or oesophagitis can be initially treated with standard doses of PPI. It’s advised that treatment should be stopped after four to eight weeks.

However, PPI therapy shouldn’t be stopped for patients with severe oesophagitis or complications, such as oesophageal stricture or Barrett's oesophagus.

 

 

What about GORD in the long term?

Unfortunately, most GORD cases relapse after stopping treatment. Relapse can take some months, however.

If a relapse occurs, treatment should be restarted and once again have their treatment stopped after the four to eight weeks. Also, ENRD can be maintained using medication only on days when patients feel their symptoms returning.

 

 

Is there surgery available for GORD and its related conditions?

Restoration of the complete functional ability of the lower oesophageal sphincter is the aim of anti-reflux surgery, in order to reduce reflux. 

To do this, the gastric fundus is wrapped around the lower oesophagus. This process is known as fundoplication. Surgery lasts for 10 years and long-term PPI therapy is equally effective over five. Fundoplication can be done via open and laparoscopic (key hole) surgery.

Also, endoscopic anti-reflux procedures have recently become available. These include applying radiofrequency energy to the lower oesophagus to produce a stenosis, endoscopic suturing (where it is narrowed via stitching) to produce a fold at the lower oesophagus. Then bulking agents are injected into the lower oesophageal sphincter.

 

 

What are the associated complications of GORD?

Patients with reflux oesophagitis, rather than those who have ENRD, are those that are most likely to have complications.

Potential complications of GORD include:

 

  • Oesophageal ulceration

 

There is a low risk of bleeding and perforation associated with ulceration. It is found in the most severe grades of oesophagitis. Treatment is a high dose of PPIs and a repeat endoscopy after six to eight weeks of treatment, checking for ulcer healing and excludes cancer

 

  • Oesophageal (peptic) stricture

 

Stricture can cause problems with swallowing of solid foods and result in a blockage (food bolus impaction). Urgent endoscopy or a barium swallow is required and treatment is with a high dose of PPIs and endoscopic dilatation, which is a procedure that stretches a narrowed area of your oesophagus.

 

  • Barrett's oesophagus and oesophageal adenocarcinoma

 

Chronic GORD and acid damage to the lower oesophagus can result in Barrett's oesophagus. It is the replacement of native tissue by a length of metaplastic columnar epithelium. This is tissue that has transformed into another column-type tissue which is found naturally in the stomach, small and large intestines, but the transformational nature means it is considered to be an early stage of cancer called adenocarcinoma (cancer that begins in glandular, or secretory, cells). The patient is said to have short segment Barrett's oesophagus if the segment is less than three centimetres in length. The risk of early cancer is low at about one per cent, maybe even less. Patients with multiple biopsies of the Barrett's segment are offered endoscopy every one to three years. More frequent endoscopic surveillance is offered If dysplasia is present and long-term high-dose PPI therapy for all patients with Barrett's oesophagus is recommended.

 

 

 

If you'd like to read an introductory summary of GORD, visit part one in this series or discover about GORD diagnosis in part two.

Dr Thillainayagam can assist regarding your GORD and gastroenterology-related concerns. Visit his Top Doctors profile here to arrange and appointment.

By Dr Andrew Thillainayagam
Gastroenterology

Dr Andrew Thillainayagam is a consultant physician and gastroenterologist based in London. He specialises in abdominal pain, colonoscopy and endoscopy alongside gastroscopy, liver disease and inflammatory bowel disease (IBD). He practices privately for The London Clinic in central London and Imperial College Private Healthcare in west London and also works for the Imperial College Healthcare NHS Trust as one of the lead interventional endoscopists. 

Dr Thillainayagam always aims to give the best service to his patients; he makes use of cutting-edge techniques and technologies at the forefront of the field of interventional endoscopy.

Dr Thillainayagam graduated from the University of Manchester's highly-regarded medical school in 1984. He undertook further training in the London region at St Bartholomew's and St Mark's Hospitals and in the Oxford region at John Radcliffe Hospital and the Royal Berkshire Hospital.

Dr Thillainayagam's highly-qualified practical expertise is complemented by his respected clinical academic reputation. He has been a consultant lecturer and was promoted to honorary senior lecturer in medicine at Imperial College Healthcare NHS Trust, where he has remained in this top role since 1996. He also manages an undergraduate teaching firm.

Mr Thillainayagam's clinical interests include therapeutic endoscopy, complex functional disorders of the digestive system and hepatopancreaticobiliary medicine as well as inflammatory bowel disease. At present, he is researching into cholangiocarinoma, iron deficiency anaemia and novel endoscopic imaging alongside bile salt malabsorption and the palliation of GI cancer. 

Mr Thillainayagam is chairman of the NW Thames Gastroenterology Group and has written extensively on the subject of gastroenterology. His work has been featured in prominent peer-reviewed journals. He is also on the Clinical Services committee of the British Society of Gastroenterology and an executive committee member of The Medical Council on Alcohol (MCA).

View Profile

Overall assessment of their patients


This website uses our own and third-party Cookies to compile information with the aim of improving our services, to show you advertising related to your preferences as well analysing your browsing habits. You can change your settings HERE.